Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

OWC Pharmaceutical Research Corp OWCP

OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company's Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.


GREY:OWCP - Post by User

Comment by B8lair8on Feb 11, 2019 1:07am
306 Views
Post# 29345225

RE:RE:RE:Massive volume today ...

RE:RE:RE:Massive volume today ...Find this over on Investors hub. Up to a 500 to 1 reverse split, that would be it.
B.

FOR the authorization of our Board of Directors to effect one reverse stock split of our outstanding Common Stock, $0.00001 par value per share, at any ratio up to 1-for-500, at such time as our Board of Directors shall determine, in its sole discretion, during the Company’s 2019 fiscal year ending December 31, 2019
<< Previous
Bullboard Posts
Next >>